Study of the medicinal ingredient in Woulgan® Biogel, SBG, is being published:
Data from Biotec BetaGlucans’ earlier clinical testing of SBG on diabetic foot ulcers have been accepted for publication in Journal of Diabetes Investigation.
The paper with the title “Macrophage stimulating agent soluble yeast b-1,3/1,6-glucan as a topical treatment of diabetic foot and leg ulcers: A randomized, double blind, placebo-controlled phase II study” is to be published in the 2014 volume of Journal of Diabetes Investigation. An open access of the paper is now available online ahead of publication (http://onlinelibrary.wiley.com/doi/10.1111/jdi.12165/pdf).
The results from this study showed a clear beneficial effect of SBG treatment in healing of diabetic foot ulcers. A statistical significant effect was apparent as early as only 8 weeks from start of treatment. SBG is the proprietary medicinal substance made by Biotec BetaGlucans and is the medicinal substance included in the Woulgan® Biogel product. Woulgan® Biogel is a novel and active wound healing biogel currently awaiting CE-mark.
Within chronic wound care there is an unspoken need for unbiased, blinded and controlled studies of the treatment options available. This publication is part of the solid documentation of the effects of SBG in wound treatment provided by Biotec BetaGlucans, supporting the usefulness of Woulgan® Biogel in the marketplace.
CEO Svein Lien says: “We are looking forward to getting our Woulgan® Biogel product out in the marketplace and this publication will be a great support to show the effect of the active ingredient in this product. Customers do prefer to consider information which has been through the quality check of an independent journal, making this publishing is a very important step in our preparation for launch.”
About Biotec BetaGlucans and Woulgan® Biogel
Biotec BetaGlucans is a wholly owned subsidiary of Biotec Pharmacon ASA. Biotec BetaGlucans develops and manufactures novel immunomodulating products. Newly developed Woulgan® Biogel for use in wound healing contains the company’s proprietary substance SBG® (soluble beta-glucan), which strengthens the organism’s ability to heal wounds. Woulgan® Biogel is a sterile gel containing water, glyserol, 2% SBG, and carboxymethylcellulose. The product does not contain any preservatives. The Woulgan® Biogel is a single-patient primary dressing for one-time use on skin wounds including diabetic ulcers, bedsores, leg ulcers, transplantation wounds, post-surgery wounds, trauma wounds, first- and second-degree burns, abrasions, and cuts. The company has entered into an agreement with world leaders Smith & Nephew for market evaluation of Woulgan® Biogel based on regular clinical use. The test period will commence immediately upon receipt of the CE-mark.
Contact details:
CEO Svein W. F. Lien, tel +47 922 89 323
CSO Rolf E. Engstad, tel +47 959 41 542